Bioharvest announces completion of stage 1 development for cdmo contract with nasdaq-listed pharmaceutical company

Successful progression validates botanical synthesis platform for a variety of molecule types rehovot, israel--(newsfile corp. - may 12, 2025) - bioharvest sciences inc. (nasdaq: bhst) (fse: 8mv0) ("bioharvest" or the "company"), a company pioneering its patented botanical synthesis technology platform, today announced that the company's previously announced cdmo contract with a nasdaq-listed pharmaceutical company has progressed from stage 1 to stage 2 - providing further validation of the versatility of the company's botanical synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing. stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product.
CDMO Ratings Summary
CDMO Quant Ranking